{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
N-(Fluorenyl-9-methoxycarbonyl)leucine (NPC 15199) is an organic compound that demonstrates antiinflammatory effects. NPC 15199 and other N-(9-fluorenylmethoxycarbonyl)-protected amino acids are demonstrated to block recruitment of neutrophils into inflammatory lesions and to inhibit T-cell activation in vitro, and are classified as leumedins. N-(Fluorenyl-9-methoxycarbonyl)leucine is described to act as a chemically distinct ligand and modulator of PPARγ (peroxisome proliferator-activated receptor γ). N-(Fluorenyl-9-methoxycarbonyl)leucine is demonstrated to increase intracellular Ca2+ and to mobilize Ca2+ stores in human bladder female transitional cancer (BFTC) cells.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
L-822179 is a triazolophthalazine that selectively attenuates the effects of GABA at GABA(A) receptors containing an alpha5 subunit. It is an orally active, functionally selective compound, which enhances cognition in animals without anxiogenic or convulsant effects. The dose-limiting adverse event of L-822179 is dizziness and/or light-headedness. L-822179 does not improve cognitive performance in the elderly; indeed the dose of 4 mg actually significantly impairs performance. In this regard, it could therefore be considered that this study is a failed trial in so far as the positive control, lorazepam, does not show the anticipated effect.
